论文部分内容阅读
目的探讨伏立康唑治疗血液病合并侵袭性真菌感染的疗效及临床分析。方法 2010年6月至2012年6月期间,我院诊治的41例血液病合并侵袭性真菌感染患者,给予伏立康唑治疗,对其临床疗效及不良反应,进行观察。结果 41例伏立康唑治疗患者中,4例治愈、18例显效、10例进步、9例无效,总有效率为53.7%,其中治愈率和显效率分别为9.8%和43.9%。结论对于血液病合并侵袭性真菌感染患者,伏立康唑具有较好的临床疗效,并且不良反应相对较少,值得临床推广。
Objective To investigate the efficacy and clinical analysis of voriconazole in the treatment of hematological diseases complicated with invasive fungal infection. Methods From June 2010 to June 2012, 41 patients with blood diseases complicated with invasive fungal infection treated in our hospital were treated with voriconazole, and their clinical efficacy and adverse reactions were observed. Results Among the 41 voriconazole-treated patients, 4 were cured, 18 were markedly effective, 10 were progressive, 9 were ineffective, and the total effective rate was 53.7%. The cure rate and effective rate were 9.8% and 43.9% respectively. Conclusion Voriconazole has a good clinical curative effect in patients with blood diseases complicated with invasive fungal infection and has relatively fewer adverse reactions, which is worthy of clinical promotion.